Gender Dysphoria
The mean (SD) GPSQ score of the cohort at baseline was 45.1 (6.4), with all individuals reporting clinically significant levels of gender dysphoria (GPSQ score >28). Compared with controls, in individuals receiving testosterone, there was a significant reduction in GPSQ score over 3 months’ follow-up (mean difference, −7.2 points; 95% CI, −8.3 to −6.1 points; 